(Reuters) - The first dose of Pfizer Inc and BioNTech's COVID-19 vaccine is 85% effective, a study of Israeli healthcare workers published in The Lancet here medical journal has found. The research ...
A post-marketing trial finds the oral antiviral achieves effective blood concentrations in at-risk children aged 6 years or older with mild-to-moderate COVID.
Pfizer and BioNTech said Monday that late-stage trials of its COVID-19 vaccine in children show that the shots were safe and effective in kids aged between 5 and 11. The results mark a key step in ...
The analysis included 14,019 cases of the Delta variant – 166 of whom were hospitalised – between April 12 and June 4.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results